A 64-week, two-arm, randomized, double-masked, multi- center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration.
Principal Investigator – Prof. Ian McAllister
For further information about this study please visit the Clinical Trials Registry (NCT04005352) or contact the Clinical Trials Office on (08) 9381 0750 or email clinicalresearch@lei.org.au
